Bromodomain inhibitors

1. A compound of Formula (IIa), or a pharmaceutically acceptable salt thereof,

wherein,

R 2 is CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;

X6 is C—H;

X5 is C—R 5 ;

R 5 is hydrogen, halogen, —OH, —CN, —OR 61 , —NHR 61 , —N(R 61 ) 2 , alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, wherein each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

R 6 is hydrogen, halogen, —OH, —CN, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, dialkylamino, cycloalkylalkylamino, alkoxy, or cycloalkylalkoxy;

R A is

X2 is N;

R 13 is —Y—Z;

Y is selected from a bond, or —CH 2 —;

Z is selected from —SO 2 R 21 , —N(R 22 )SO 2 R 21 , —SO 2 N(R 22 ) 2 , —N(R 22 )SO 2 N(R 22 ) 2 , —CON(R 22 ) 2 , —N(R 22 )CO 2 R 21 , —N(R 22 )CON(R 22 ) 2 , —N(R 22 )COR 21 , —OC(O)N(R 22 ) 2 , —OSO 2 N(R 22 ) 2 , or —N(R 22 )SO 3 R 21 ;

X3 is N;

X4 is C—R 15 , wherein R 15 is hydrogen, halogen, —CN, alkyl, or alkoxy;

R 16 is hydrogen, halogen, or —W—X, wherein W is a bond, —O—, —S—, or —NH—, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and

each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, halogen, —OR 61 , or alkyl; R 61 is alkyl; and R 6 is hydrogen, halogen, alkyl, alkoxy.

3. The compound of claim 2 having the structure of Formula (IIb), or a pharmaceutically acceptable salt thereof,

wherein,

R 2 is CH 3 ;

X6 is C—H;

X5 is C—R 5 ;

R 5 is hydrogen;

R 6 is halogen or alkyl;

R A is

X2 is N;

R 13 is —Y—Z;

Y is selected from a bond, or —CH 2 —;

Z is selected from —SO 2 R 21 , —N(R 22 )SO 2 R 21 , —SO 2 N(R 22 ) 2 , —N(R 22 )SO 2 N(R 22 ) 2 , —CON(R 22 ) 2 , —N(R 22 )CO 2 R 21 , —N(R 22 )CON(R 22 ) 2 , —N(R 22 )COR 21 , —OC(O)N(R 22 ) 2 , —OSO 2 N(R 22 ) 2 , or —N(R 22 )SO 3 R 21 ;

X3 is N;

X4 is C—R 15 , wherein R 15 is hydrogen, halogen, —CN, alkyl, or alkoxy;

R 16 is —W—X, wherein W is a bond, —O—, —S—, or —NH—, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and

each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is halogen.

5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is alkyl.

6. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is C 1 -C 3 alkyl.

7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is C 1 alkyl.

8. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y is a bond.

9. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y is a —CH 2 —.

10. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Z is —SO 2 R 21 .

11. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Z is —N(R 22 )SO 2 R 21 .

12. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl.

13. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is alkyl.

14. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is C 1 -C 2 alkyl.

15. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 22 is hydrogen.

16. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O—.

17. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond.

18. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is alkyl.

19. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is aryl.

20. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is cycloalkylalkyl.

21. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O— and X is aryl.

22. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O— and X is cycloalkylalkyl.

23. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond and X is alkyl.

24. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond and X is cycloalkylalkyl.

25. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

26. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

27. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

28. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

29. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

30. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (IIa) as described in claim 1 , or a pharmaceutically acceptable salt thereof.